Revolution Medicines is expected to report a Q2 2026 consensus revenue of $1.8 million and an adjusted EPS loss of $1.93, while the stock currently trades at $182.30 against an average analyst target of $194.24. The primary focus for the market is the regulatory and clinical trajectory of daraxonrasib (RMC-6236), the company's leading RAS-multi inhibitor currently in Phase 3 trials.
Investors are optimistic following recent survival data and an expedited review status from the European Medicines Agency, which could accelerate the path to market. However, the company's widening losses and projected FY2026 operating expenses of $1.7 billion to $1.8 billion remain key points of scrutiny regarding its long-term cash runway and commercial readiness.